TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00330980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Pravastatin (Pravachol)
Description: Participants will receive 40 mg of pravastatin for 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg Simvastatin
Description: Participants will receive 20 mg of simvastatin for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo for 6 months.
Study: NCT02693080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAPP-Seq
Description: Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) is an assay which allows quantitative assessment of the levels of circulating-tumor DNA in the blood sample.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isovue-200
Description: Contrast agent

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Computed Tomography Perfusion Imaging
Study: NCT03356353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: 20 mg tablets
Study: NCT00615693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEB071
Study: NCT04230265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Non-IMP)
Description: Intravenous infusion over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (Non-IMP)
Description: Intravenous infusion over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Non-IMP)
Description: Intravenous infusion over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine (Non-IMP)
Description: Intravenous infusion over 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM123 (IMP)
Description: Intravenous Infusion for 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TM123 (IMP)
Description: Intravenous Infusion for 20 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UniCAR02-T (IMP)
Description: Intravenous infusion of single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UniCAR02-T (IMP)
Description: Intravenous infusion of single dose
Study: NCT04726930

Intervention type: PROCEDURE
Intervention: Intercostal nerve blocks
Description: Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.

Intervention type: PROCEDURE
Intervention: Intercostal nerve blocks
Description: Intercostal nerve block is a regional anesthetic procedure for peri-operative pain management. It inhibits the action of the ipsilateral sensory and motor branches, and produces analgesic effects at the targeted thoracic level.

Intervention type: PROCEDURE
Intervention: Paravertebral block
Description: Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen

Intervention type: PROCEDURE
Intervention: Paravertebral block
Description: Paravertebral block is the technique of injecting local anesthetic alongside the thoracic vertebra close to where the spinal nerves emerge from the intervertebral foramen. This produces unilateral, segmental, somatic, and sympathetic nerve blockade, which is effective for anesthesia and in treating acute and chronic pain of unilateral origin from the chest and abdomen
Study: NCT02704949

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 1/4 fluoroscopy dose
Description: Use of 1/4 fluoroscopy dose while ureteroscopy is being performed

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Full-dose
Description: Use of full fluoroscopy dose while ureteroscopy is being performed
Study: NCT00834600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olmesartan, hydrochlorothiazide, amlodipine
Description: hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olmesartan, hydrochlorothiazide, amlodipine
Description: hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP \>140 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrochlorothiazide (HCTZ) or olmesartan
Description: HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) or olmesartan
Description: HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure \>140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
Study: NCT02585986

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: daily intake of 1 capsule probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily intake of 1 capsule containing placebo
Study: NCT03861416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine 1.4% 500 ml
Description: Infusion of L-arginine 1.4% solution by 500 ml (2 vials 250 ml each) IV daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine 1.4% 250 ml + placebo 250 ml
Description: Infusion of L-arginine 1.4% solution 250 ml IV daily for 10 days and placebo infusion by 250 ml IV daily for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solution
Description: Infusion of Ringer's solution by 500 ml (2 vials 250 ml each) IV daily for 10 days
Study: NCT03777046

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive Standard of care treatment. SOC treatment includes social work consult with information about follow up options for PPD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SOC with Psychology Therapy (CBT)
Description: Mothers that meet inclusion criteria for the study, that score 10 or more on the Edinburgh Postpartum Depression Scale (EPDS) that will receive the experimental intervention. Intervention includes SOC treatment as well as psychology therapy (CBT) in the hospital.
Study: NCT00000401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral bovine type II collagen
Description: Drug can be interrupted or stopped for suspected adverse events.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral bovine type II collagen
Description: Drug can be interrupted or stopped for suspected adverse events.
Study: NCT01864681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib and Metformin
Description: Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gefitinib and placebo
Description: Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
Study: NCT02860234

Intervention type: DRUG
Intervention: Oxaliplatin

Intervention type: DRUG
Intervention: Oxaliplatin

Intervention type: DRUG
Intervention: Oxaliplatin

Intervention type: DRUG
Intervention: Capecitabine

Intervention type: DRUG
Intervention: Capecitabine

Intervention type: DRUG
Intervention: Capecitabine

Intervention type: RADIATION
Intervention: intensity modulated radiotherapy

Intervention type: RADIATION
Intervention: intensity modulated radiotherapy

Intervention type: RADIATION
Intervention: intensity modulated radiotherapy

Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA

Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA

Intervention type: PROCEDURE
Intervention: DRE-Endoscopy-MRI-CEA

Intervention type: PROCEDURE
Intervention: Nonoperative Management

Intervention type: PROCEDURE
Intervention: Nonoperative Management

Intervention type: PROCEDURE
Intervention: Local Excision

Intervention type: PROCEDURE
Intervention: Total Mesorectal Excision

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Study: NCT04277481

Intervention type: OTHER
Intervention: 10 minute cold pack
Description: 10 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.

Intervention type: OTHER
Intervention: 12 minute cold pack
Description: 12 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.

Intervention type: OTHER
Intervention: 15 minute cold pack
Description: 15, min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.

Intervention type: OTHER
Intervention: 20 minute cold pack
Description: 20 min package (35 \* 29 cm) will be wrapped with a towel and applied to the rectus femoris part of the quadriceps.
Study: NCT02919891

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires

Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaires
Study: NCT00595881

Intervention type: DEVICE
Intervention: Bedside emergency ultrasound
Description: Ultrasound will be performed on the lesion in question.
Study: NCT01481714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium picosulphate, magnesium oxid and citric acid
Description: * A sachet mixed with 250 mL of water at 18:00 pm~* A sachet mixed with 250 mL of water at 21:00 pm~* A minimum of 4 litres of fluid were recommended throughout the preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium picosulphate/magnesium oxide and citric acid
Description: The day before the procedure:~- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids~The day of the procedure:~* A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.~* A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am.
Study: NCT00374062

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation therapy 1
Description: relaxation therapy 1

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relaxation therapy 2
Description: relaxation therapy 2

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: relaxation therapy 3
Description: relaxation therapy 3
Study: NCT02409264

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualised Homeopathic Remedy
Description: Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
Study: NCT01289561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol + Caffeine Beverage
Description: 14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol + Caffeine-placebo
Description: 14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
Study: NCT03988894

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mDASHNa App
Description: The functions of the app will include: (a) antihypertensive dietary education; (b) dietary self-assessment; (c) automatic feedback according to dietary self-assessment; (d) blood pressure monitoring; and (e) automatic feedback according to blood pressure data.
Study: NCT00562536

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord clamping
Description: Delay of umbilical cord clamping 30 to 45 seconds
Study: NCT03960385

Intervention type: BIOLOGICAL
Intervention: CYD-TDV
Description: Dengue vaccine

Intervention type: BIOLOGICAL
Intervention: CYD-TDV
Description: Dengue vaccine
Study: NCT02319564

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone and Salbutamol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Aerochamber Max®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerochamber Max®

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aerochamber Max®
Study: NCT04198311

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: CBT-I will be delivered individually, in five weekly sessions. Intervention components include sleep hygiene, sleep restriction, stimulus control, relaxation, cognitive therapy.
Study: NCT03593005

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment at Low Altitude (470m above sea level)
Description: Assessment at Low Altitude (in Zurich; 470m above sea level) in order to compare this data with High altitude exposure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exposure to High Altitude (2500m above sea level)
Description: Exposure to High Altitude (Säntis; 2500m above sea level) for approximately 5 hours
Study: NCT05997173

Intervention type: OTHER
Intervention: Control
Description: Investigation of scale of control

Intervention type: OTHER
Intervention: Non erosive OLP
Description: Investigation of cale of non erosive OLP patients

Intervention type: OTHER
Intervention: Erosive OLP
Description: Investigation of cale of erosive OLP patients
Study: NCT01875874

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ELAD
Description: Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
Study: NCT03286634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-coli L-asparaginase
Description: Given IM or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-coli L-asparaginase
Description: Given IM or IV
Study: NCT01201824

Intervention type: PROCEDURE
Group type: OTHER
Intervention: intracavitary ultrasound
Description: intracavitary ultrasound done during surgical intervention
Study: NCT02973295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Capsules contains 100 mg of silymarin
Study: NCT03286634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO
Study: NCT02973295

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Capsule will be identical in shape, size and color, packed in the same way like verum
Study: NCT03286634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, PO or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, PO or IT
Study: NCT01091038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basic Clinical Decision Support
Description: The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine Care
Description: Routine Care
Study: NCT02520544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade stem
Description: Total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accolade II stem
Description: Total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident/Tritanium cup
Description: Total hip replacement
Study: NCT03286634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given IT
Study: NCT02520544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trident/Tritanium cup
Description: Total hip replacement
Study: NCT04483193

Intervention type: DIAGNOSTIC_TEST
Intervention: Duplex ultrasound
Description: Point-of-Care compression ultrasound test combined with colour doppler imaging in the range from the groin to the popliteal region of both lower extremities.
Study: NCT01421238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
Study: NCT03286634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV, IT or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT01263470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT02057640

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: 20mg, on day 1, 3, 5, 15, 17, 19, 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20mg, on day 1, 2, 8, 9, 15, 16, 28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN9708
Description: 4mg on day 1, 8, 15, 28
Study: NCT02374788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer intervention
Description: Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer intervention
Description: Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group meetings
Description: Participants receive 12 group meetings over two years' time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual consultations
Description: Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
Study: NCT03709069

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Albumin supplementation
Description: Enteral supplementation by albumin of boiled egg as 2mg per kg body weight.
Study: NCT03687294

Intervention type: DEVICE
Intervention: enzyme linked immunosorbent assay (ELISA)
Description: ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors

Intervention type: DEVICE
Intervention: enzyme linked immunosorbent assay (ELISA)
Description: ELISA measure MYB in tissue biopsy in benign and malignant salivary gland tumors
Study: NCT00003566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: videothoracoscopy